聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎

Efficacy of Peginterferon in Combination with Ribavirin in Treatment of Patieuts with Chronic hepatitis C

目的:评价聚乙二醇干扰素联合利巴韦林治疗慢性丙型病毒性肝炎的临床疗效。方法:64例丙型病毒性肝炎患者分为治疗组与对照组,治疗组48例,用聚乙二醇干扰素联合利巴韦林治疗,聚乙二醇干扰素180μg每周1次皮下注射;对照组16例,用安福隆联合利巴韦林治疗,安福隆300万U隔日1次肌肉注射,两组利巴韦林的剂量均为750～1050mg·d^(-1),疗程均为48周。结果:聚乙二醇干扰素联合利巴韦林治疗慢性丙型病毒性肝炎的持续应答率为88.1%,对照组持续应答率41.7%,两组比较差异,有统计学意义(P<0.01)。结论:聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎的疗效疗效优于普通干扰素。

Objective：To evaluate the efficacy and safety of peginterferon plus ribavirin in the freatment of patients with chron ic hepatitis C. Methods： Sixty-four patients with chronic hepatitis C were randomly divided into treatment group and control group, Forty-eight patients in the treatment group received 180μg of peginterferon subcutaneously once a week plus ribavirin o rally 750- 1050 mg per day for 48 weeks totally. Sixteen patients in control group received 3 million units of Recombinant In terferon α-2b intramuscular injection once every other day plus ribavirin orally 750- 1 050 mg per day for 48 weeks totally. Results： 88.1% of the patients in the treatment group had a sustained virologic response, as compared with 41. 70% in control group（P〈0.01 ）. Conclusion：In the patients with chronic hepatitis C,a regimen of peginterferon given once a week plus ribavitin is more effective than that of Recombinant Interferon α-2b given once every other day plus ribavirin.